

**ANNUAL REPORT OF THE
NATIONAL CENTRE FOR ADVERSE DRUG REACTION MONITORING, NPCB 2013**

1. Membership of Malaysian Adverse Drug Reactions Advisory Committee (MADRAC) till the end of 2013

MADRAC Members (Alternate members)	
Mr Tan Ann Ling Director of Pharmacy Regulatory National Pharmaceutical Control Bureau	Chairman
Ms Sameerah Shaikh Abdul Rahman Deputy Director Centre for Post-Registration of Products National Pharmaceutical Control Bureau	Secretary
Ms Noorizam Ibrahim Secretary of Drug Control Authority National Pharmaceutical Control Bureau	Committee Member
Prof. Datuk Dr. Jeyaindran Tan Sri Sinnadurai, PJ Deputy Director General of Health (Medical) Ministry of Health <i>(Dr. Hjh Rosaida Mohd. Said)</i>	Committee Member
Datuk Dr Roshidah Baba Head of Dermatology Services Head of Department and Senior Consultant Dermatologist, Hospital Melaka <i>(Dr Rohna Ridzwan)</i>	Committee Member
Dr Lim Chong Hum Head of Department and Senior Consultant Psychiatrist, Hospital Ampang <i>(Dr Zanariah Mat Saher)</i>	Committee Member
Dr G.R. Letchuman Ramanathan Head of Department and Senior Medical Consultant (Endocrinology), Hospital Taiping <i>(Dr. Padmini Menon)</i>	Committee Member
Dato' Dr Gun Suk Chyn Head of Department and Senior Medical Consultant (Rheumatology), Hospital Tuanku Ja'afar <i>(Dr Muhaini Othman)</i>	Committee Member
Dato' Dr Tan Chwee Choon Head of Department and Senior Medical Consultant (Nephrology), Hospital Tuanku Ampuan Rahimah <i>(Dr Sunita Bavanandan)</i>	Committee Member
Assoc. Professor Datin Dr. Zorah binti Aziz Department of Pharmacy, Faculty of Medicine University of Malaya <i>(Prof. Dr. Mohamed Mansor Manan)</i>	Committee Member

Dr. Rohani Jahis Head Of The Vaccine Prevention Of Disease/Food&Water Borne UD54 Disease Control Division (Dr. Jamiatul Aida Md. Sani)	Committee Member
Ms. Anis Talib Deputy Director Formulary and Pharmacoeconomic Section, Pharmaceutical Services Division (Ms. Azuwana Supian)	Committee Member
Ms. Wendy Khor Hooi Chin Malaysian Pharmaceutical Society (MPS) (Mr. Lam Kai Kun)	Committee Member
Ms. Eliza Basir Association of Private Hospitals of Malaysia (APHM) (Ms. Lee Seng Dee)	Committee Member
Dr. Koh Kar Chai Malaysian Medical Association (MMA) (Dr. Azizan Binti Abdul Aziz)	Committee Member
Dr. Steven Chow Federation of Private Medical Practitioners' Association Malaysia (FPMPAM) (Dr. G.Shanmuganathan)	Committee Member

2. MEETINGS

During the calendar year 2013, six (6) meetings were conducted with a total of 11368 adverse drug reactions reports were reviewed by the committee

3. ANALYSIS OF ADVERSE DRUG REACTIONS REPORTS

A detailed review and analysis of the adverse drug reactions (ADR) reports received during the year 2013 was conducted (Appendix 1).

4. Drug Safety Issues Discussed by MADRAC in 2013 and Resulting Risk Minimisation Actions

During the course of 2013, the following regulatory actions were proposed by MADRAC. These are the actions on certain pharmaceutical products following the Alerts received from other international regulatory agencies as well as data from local institutions.

MADRAC Meeting Date	Safety Issue Discussed	MADRAC Recommendation/ Resulting Actions			
		PI Update	DHPC	Publication of article	Further review
21/2/2013	Pradaxa [®] (dabigatran etexilate mesylate): New Contraindication For Pradaxa In Patients With Prosthetic Valves	✓		✓	
	Mabthera [®] (rituximab): Association with Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS)	✓		✓	
18/4/2013	Prolia [®] and Xgeva [®] (denosumab): Association With Risk of Anaphylactic Reactions and Atypical Femoral Fracture	✓		✓	
	Trimetazidine-containing Products: New Recommendations On The Restriction Of Use	✓			
	Miacalcic [®] (calcitonin salmon): European Medicines Agency (EMA) Suspends The Intranasal Formulations And Recommends New Restrictions For All Injectable Formulations				✓
	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Association With Cardiovascular Risks				✓
13/6/2013	Avastin [®] (bevacizumab): Association With Necrotising Fasciitis	✓			
	Champix [®] (varenicline): Association With Risks of Cardiovascular Adverse Events: A Review Update				✓
	Diane 35 [®] (cyproterone Acetate, ethinylestradiol): Suspension of Marketing Authorisation in France	✓		✓	
	Codeine-containing products: Adverse Drug Reactions Associated with Children (21 months-9 years) Undergoing Adenotonsillectomy and/or Tonsillectomy			✓	
22/8/2013	Trobalt [®] (retigabine): Restriction Of Indication Resulting From Observed Pigment Changes (Discolouration) of Ocular Tissue (Including Retina), Nails, Lips, and/or Skin	✓	✓		
	Votrient [®] (pazopanib)- Important Change in Frequency for Serum Liver Enzymes Monitoring	✓	✓		
	Mabthera [®] (rituximab): New Risk Management of Hepatitis B Reactivation in Patients Prior to Initiation of Therapy	✓	✓	✓	
	Paracetamol-containing products: Association with Serious Skin Adverse Drug Reactions				✓

MADRAC Meeting Date	Safety Issue Discussed	MADRAC Recommendation/ Resulting Actions			
		PI Update	DHPC	Publication of article	Further review
	Lovastatin-containing products: New Restrictions To Reduce Muscle Injury				✓
22/8/2013 & 24/10/2013	Hydroxyethyl Starch (HES)-containing products: Suspension of Marketing Authorisation by European Medicines Agency (EMA) Due To Increased Mortality And Risk Of Kidney Injury Requiring Dialysis	✓		✓	
24/10/2013	Erythropoetin Stimulating Agents: Adverse Drug Reaction Reports Associated with Pure Red Cell Aplasia (PRCA) Received by National Pharmaceutical Control Bureau				✓
	Lariam [®] (mefloquine): Association with Visual Disturbance Including Optic Neuropathy	✓		✓	
	Oral Ketoconazole-containing products: Suspension of Marketing Authorisation by European Medicines Agency (EMA) Due To Association with the Risk of Hepatotoxicity	✓	✓	✓	
12/12/2013	Protaxos [®] (strontium ranelate): Association With Increased Risk Of Serious Heart Problems	✓	✓	✓	
	Tygacil [®] (tygecycline): Association With Increased Risk of Death			✓	
	Erythropoetin Stimulating Agents -Associated Pure Red Cell Aplasia (PRCA) Adverse Drug Reaction Reports in Malaysia: An Update Following Contraindication of the Subcutaneous Route for Eprex in Singapore				✓
	Xeloda [®] (capecitabine): Association with Toxic Epidermal Necrolysis (TEN) and Steven Johnson Syndrome (SJS)	✓	✓		
	Jevtana [®] (cabazitaxel): Potential For Medication Error During Preparation	✓	✓		
	Frisium [®] (clobazam): Association with Toxic Epidermal Necrolysis (TEN) and Steven Johnson Syndrome (SJS)	✓	✓		

5. ACTIVITIES

During the year of 2013, we continue to enhance our ADR report rate and the quality of report received through various activities such as training and awareness programme.

i) Training/short course/workshop

a) Training on ADR reports analysis and causality assessment

Pharmacists various hospital in Selangor, Malacca and Negeri Sembilan gathered in NPCB for this short training. This training is focusing on assessment of ADR reports, critical question that need to ask the prescriber and how to do a causality assessment based on criteria set by World Health Organization (WHO).

- b) Kursus Amalan Farmasi kepada Ketua Pegawai Farmasi dan Pegawai Farmasi Kesihatan Awam

Chief Pharmacists and pharmacists from public health from all over Malaysia attended this short course held in Port Dickson, Negeri Sembilan. Adverse Drug Reactions reporting is one of the topics that had been discussed together with in group activity of ADR case study.


- c) 1st National Conference on Quality Use of Medicines Conference

Quality Used of Medicine and Pharmacovigilance was one topic of the parallel programme in this conference. It focused more on the importance of pharmacovigilance in quality used of medicine.

ii) Awareness programme


1. Post Marketing Activities at the Generic Medicine Awareness Programme - 8 programme
2. Pharmacovigilance, Adverse Drug Reaction, AEFI Handling and Reporting General Talk – 11 programme
3. Consumer Awareness Programme – 1 programme

ADR and AEFI Reports Received (2009-2013)




ADR Reports without AEFI	5636	5550	6202	8199	9678
AEFI Reports	214	1529	3183	1903	1795

ADR REPORTS BY REPORTERS




MOH Pharmacist	3358	4160	4267	5106	6283
MOH Nurse	25	388	2063	1636	905
MOH Doctors	1340	1418	1295	1627	1560
Other Govt Agency	0	0	0	67	621
Product Registration Holder	686	612	691	1066	1235
GP/Private Specialist	144	248	185	310	119
University	281	234	142	151	187
Others	16	19	742	206	303


ADR REPORTS BY STATE FROM MOH FACILITIES 2013




ADR REPORTS BY AGE GROUP





ADR REPORTS BY RACE




ADR REPORTS BY GENDER





ADR REPORTS BY PHARMACOLOGICAL GROUP



ANALYSIS OF ADR BY SYSTEM ORGAN CLASS

